Zolpidem: uses, dosing, side effects & brands

Ambien (Zolpidem Tartrate) is a gamma-aminobutyric acid a receptor positive modulator used to treat Sleep Initiation and Maintenance Disorders.

The FDA classifies zolpidem as a gamma-aminobutyric acid a receptor positive modulator. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

The label treats alcohol as a CNS depressant. It states that coadministration of zolpidem with other CNS depressants "including alcohol" increases the risk of CNS depression, and that a single-dose study demonstrated an additive adverse effect on psychomotor performance between alcohol and oral zolpidem. Taking zolpidem with alcohol raises the risk of next-day psychomotor impairment, including impaired driving. The label also notes that complex sleep behaviors (the subject of the boxed warning) can occur with or without concomitant alcohol. It advises against driving or activities requiring full alertness under these circumstances. This is an additive CNS-depression caution, not a disulfiram-like reaction. This is what zolpidem's FDA label says; alcohol advice depends on your dose and health, so confirm with your pharmacist.

Yes. The label states that use of zolpidem may lead to physical and/or psychological dependence, with risk increasing with dose and duration and greater in patients with a history of alcohol or drug abuse. It describes a specific withdrawal syndrome that can be produced by abrupt cessation or rapid dose reduction: reported symptoms range from mild dysphoria and insomnia to a syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, convulsions, and delirium. In clinical trials, placebo substitution within 48 hours of the last dose produced fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort. The label lists Withdrawal Effects among its Warnings and directs that any dose reduction or discontinuation be managed by the prescriber (symptoms are tied to rapid reduction/abrupt stopping). The boxed warning concerns complex sleep behaviors, not withdrawal, so this syndrome is not in the boxed warning. Do not stop zolpidem on your own — any change is a prescriber-managed decision.

The elimination half-life of zolpidem is about 2.5 hours (mean 2.5-2.6 hours; range roughly 1.4 to 4.5 hours) in healthy adults — that is how long the body takes to clear half of a dose. All zolpidem metabolites are inactive, so no active metabolite extends its effect; however, the half-life is much longer in people with liver cirrhosis (about 10 hours, up to ~26) and modestly longer in adults over 70, so it varies by population. Half-life is not the same as how long a drug test can detect the drug, and it varies with age, kidney and liver function.

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run zolpidem against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

We track 7 zolpidem-containing products in the U.S.: Ambien, Ambien CR, Edluar, Intermezzo, Tovalt ODT, Zolpidem Tartrate and Zolpimist. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

Across the brands we track, zolpidem is currently marketed as tablet, tablet, orally disintegrating, tablet, extended release and spray/inhaler, metered, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Yes. Our catalog lists 1 generic zolpidem product alongside the brand versions. A generic has the same active ingredient and must meet the FDA's bioequivalence standard; it usually costs less. Ask your pharmacist which one your plan covers.

The FDA's Enforcement database lists 2 recall records whose product description mentions zolpidem. The most recent: Zolpidem Tartrate Extended-Release Tablets (Jan 18, 2024). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Alcohol: the FDA label flags alcohol as something to be careful with — see the alcohol section above for what it actually says. This is what the FDA label and our cited sources say — it is not a complete list. Your pharmacist can check your own combination.

Yes. Zolpidem carries an FDA boxed warning for complex sleep behaviors — sleepwalking, sleep-driving, and doing other things while not fully awake such as preparing and eating food, making phone calls or having sex, usually with no memory of it afterward. Some of these events have resulted in serious injuries, including death. They can happen at recommended doses, in people with no history of it, and after the first or any subsequent dose. If any episode like this occurs, stop zolpidem and contact the prescriber immediately: the label contraindicates further zolpidem in anyone who has experienced a complex sleep behavior on it, and FDA's safety communication goes further, telling prescribers to avoid eszopiclone and zaleplon in that situation too. Alcohol and other CNS depressants raise the risk.

Next-morning grogginess, a drugged or hungover feeling, dizziness, headache, nausea, diarrhea and dry mouth are the usual complaints. The important part is that measurable next-morning impairment — including driving impairment — can persist even when you feel perfectly alert. That's why FDA lowered the recommended doses, particularly for women, who clear zolpidem more slowly: the recommended starting dose is 5 mg for women (5 or 10 mg for men) on immediate-release, and 6.25 mg for women on extended-release. Only take it when you have at least a full 7 to 8 hours before your planned wake-up time. Waking after 4 or 5 hours and driving is where the harm happens.

Call 911 for slow, shallow or stopped breathing, unresponsiveness, or swelling of the face, lips, tongue or throat and trouble breathing, which can be angioedema from a hypersensitivity reaction and has been reported after the first dose. Also treat any sleep-driving episode or waking to evidence you did something dangerous while not awake as urgent, not embarrassing — it's a stop-the-drug event. Combining zolpidem with opioids or alcohol is the most common route to dangerous respiratory depression, and the label warns explicitly against it. Also report new or worsening depression, agitation or thoughts of self-harm.

Take it immediately before getting into bed, not an hour ahead while you finish things around the house — that gap is where sleepwalking episodes and falls happen. Don't take it with or immediately after a meal; food slows absorption and delays onset. Don't crush or split extended-release tablets. Zolpidem is a Schedule IV controlled substance, and the label covers tolerance, dependence and withdrawal. After regular nightly use, stopping abruptly commonly produces rebound insomnia that feels worse than the original problem and convinces people they can't sleep without it — taper with your prescriber instead, and get cognitive behavioral therapy for insomnia in place first if you can.

Zolpidem is cleared fast. Its elimination half-life is about 2.5–3 hours (FDA label), so roughly 90% is gone within 11–14 hours and it is essentially eliminated in about a day. In urine, zolpidem and its metabolites are typically detectable for about 24–48 hours after a single dose, though higher or repeated doses and slower metabolism (older age, liver impairment, some drug interactions) can extend that window. In blood it is usually measurable for only about 6–20 hours. These are approximate ranges that vary by dose, formulation (immediate vs. extended-release), age, and liver function; this is general information, not medical or legal advice.

No. Zolpidem is a non-benzodiazepine 'Z-drug,' so it does not reliably trigger a standard benzodiazepine urine immunoassay and is not part of the typical 5- or 10-panel workplace test. Detecting it requires a specific test that looks for zolpidem itself, usually by GC-MS or LC-MS/MS (Mayo Clinic Laboratories, Quest, and LabCorp offer targeted zolpidem assays). If you have a prescription and are worried about a test, tell the testing lab or medical review officer in advance so the result can be interpreted correctly. Detection windows vary by person; this is not medical or legal advice.

Yes, but only with specialized testing. Hair analysis by LC-MS/MS can detect zolpidem for weeks to a few months after use, reflecting longer-term exposure rather than recent dosing, and it is used mainly in forensic or medico-legal settings—not routine screening. Hair results depend on hair length, growth rate, and dose, so they are approximate. This information is educational and not a substitute for advice from your clinician or the testing laboratory.